Effect of Intravitreal Bevacizumab Injection on Aqueous Humor Cytokine Levels in Clinically Significant Macular Edema

Ophthalmology

Volumn 116, Issue 1, 2009, Pages 80-86

  Roh, Mi In ^a   Kim, Hong Suk ^a   Song, Ji Hun ^a   Lim, Jong Baek ^a   Kwon, Oh Woong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINA MACULA EDEMA; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CHEMOKINE CCL2; CYTOKINES; FEMALE; HUMANS; INJECTIONS; INTERLEUKIN-6; INTERLEUKIN-8; MACULAR EDEMA; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 57949095207     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.09.036     Document Type: Article

References (38)

1. Bresnick G.H. Diabetic macular edema: a review. Ophthalmology 93 (1986) 989-997
2. Moss S.E., Klein R., and Klein B.E. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105 (1998) 998-1003
3. Funatsu H., Yamashita H., Noma H., et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133 (2002) 70-77
4. Shimizu E., Funatsu H., Yamashita H., et al. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol 46 (2002) 78-83
5. Petrovic M.G., Korosec P., Kosnik M., and Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol 143 (2007) 175-176
6. Harada C., Okumura A., Namekata K., et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract 74 (2006) 249-256
7. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
8. Molloy R.M., McConnell R.I., Lamont J.V., and FitzGerald S.P. Automation of biochip array technology for quality results. Clin Chem Lab Med 43 (2005) 1303-1313
9. Demircan N., Safran B.G., Soylu M., et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20 (2006) 1366-1369
10. Hoekzema R., Murray P.I., van Haren M.A., et al. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 32 (1991) 88-95
11. Hoekzema R., Verhagen C., van Haren M., and Kijlstra A. Endotoxin-induced uveitis in the rat: the significance of intraocular interleukin-6. Invest Ophthalmol Vis Sci 33 (1992) 532-539
12. Aiello L.P., and Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77 (2000) S113-S119
13. Kramer M., Goldenberg-Cohen N., Axer-Siegel R., et al. Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm 13 (2005) 305-310
14. Yoshida A., Yoshida S., Khalil A.K., et al. Role of NF-κB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39 (1998) 1097-1106
15. Hong K.H., Ryu J., and Han K.H. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105 (2005) 1405-1407
16. Kim M.Y., Byeon C.W., Hong K.H., et al. Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 579 (2005) 1597-1601
17. Yamada M., Kim S., Egashira K., et al. Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23 (2003) 1996-2001
18. Shinoda K., Ishida S., Kawashima S., et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol 83 (1999) 834-837
19. Ambati J., Chalam K.V., Chawla D.K., et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 115 (1997) 1161-1166
20. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103 (1996) 1820-1828
21. Takagi H., Otani A., Kiryu J., and Ogura Y. New surgical approach for removing massive foveal hard exudates in diabetic macular edema. Ophthalmology 106 (1999) 249-257
22. Ideta R., Yamashita H., Tanaka Y., et al. Roles of cytokines in diabetic retinopathy [letter]. Arch Ophthalmol 117 (1999) 700-701
23. Hee M.R., Puliafito C.A., Wong C., et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 113 (1995) 1019-1029
24. Otani T., Kishi S., and Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 127 (1999) 688-693
25. Sanchez-Tocino H., Alvarez-Vidal A., Maldonado M.J., et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 43 (2002) 1588-1594
26. Yang C.S., Cheng C.Y., Lee F.L., et al. Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand 79 (2001) 266-270
27. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., et al., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114 (2007) 743-750
28. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
29. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113 (2006) 992-1001
30. Heier J.S., Antoszyk A.N., Pavan P.R., et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113 (2006) 633.e1-633.e4 Epub 2006 Feb 14
31. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
32. Paccola L., Costa R.A., Folgosa M.S., et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 92 (2008) 76-80
33. Luscinskas F.W., Gerszten R.E., Garcia-Zepeda E.A., et al. C-C and C-X-C chemokines trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Ann N Y Acad Sci 902 (2000) 288-293
34. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999) 718-723
35. Poston R.N., and Johnson-Tidey R.R. Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Am J Pathol 149 (1996) 73-80
36. Yang Y.Y., Hu C.J., Chang S.M., et al. Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF-alpha stimulated human umbilical vein endothelial cells. Atherosclerosis 174 (2004) 207-213
37. Han K.H., Ryu J., Hong K.H., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111 (2005) 1439-1447
38. Oku H., Shimizu T., Kawabata T., et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590 (2008) 400-408